109 related articles for article (PubMed ID: 1970266)
1. Pharmacokinetic and pharmacodynamic studies in man with an antianginal agent 'Visacor'.
Cockshott ID; McAinsh J; Norris S
Biopharm Drug Dispos; 1990 Apr; 11(3):253-63. PubMed ID: 1970266
[TBL] [Abstract][Full Text] [Related]
2. Effects of ICI 141,292 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man.
Pringle TH; O'Connor PC; McNeill AJ; Finch MB; Riddell JG; Shanks RG
Br J Clin Pharmacol; 1986 Mar; 21(3):249-58. PubMed ID: 2870732
[TBL] [Abstract][Full Text] [Related]
3. Initial clinical experience with ICI 141,292 (Visacor), a new selective beta 1-adrenoceptor blocker with ISA--a multicentre trial in 59 patients.
Dahlöf B; Danielson M; Andersson O; Thulin T; Ohman P; Mörlin C; Boberg J; Karlberg BE; Jern S; Hansson L
Br J Clin Pharmacol; 1984 Dec; 18(6):831-6. PubMed ID: 6152175
[TBL] [Abstract][Full Text] [Related]
4. Investigation of possible pharmacokinetic and pharmacodynamic interactions between epanolol and digoxin.
Lefebvre RA; Bogaert MG; Duprez D
Eur J Clin Pharmacol; 1990; 38(5):505-7. PubMed ID: 1974206
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of epanolol in elderly patients with stable angina pectoris.
Marlier R; McAinsh J; Cockshott ID
Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):142-4. PubMed ID: 1970734
[TBL] [Abstract][Full Text] [Related]
6. A new water-soluble, selective beta-blocker with intrinsic sympathomimetic activity (ICI 141.292) in angina pectoris.
Erikssen J; Rollag A; Otterstad JE
Acta Med Scand; 1988; 223(1):35-43. PubMed ID: 2894747
[TBL] [Abstract][Full Text] [Related]
7. Immediate haemodynamic effects of a novel partial agonist, beta 1-adrenoceptor blocking drug ICI 141,292 after intravenous administration to healthy young volunteers and patients with ischaemic heart disease.
Bonde J; Svendsen TL; Lyngborg K; Mehlsen J; Trap-Jensen J
Br J Clin Pharmacol; 1987 Jan; 23(1):35-40. PubMed ID: 2880603
[TBL] [Abstract][Full Text] [Related]
8. ICI 141,292 (epanolol)--pharmacokinetics after single and repeated oral administration in the elderly with moderate renal impairment.
Laher MS; Crome P; Rakhra GS; Ankier SI; Cockshott ID
Eur J Clin Pharmacol; 1990; 39(1):71-4. PubMed ID: 1980462
[TBL] [Abstract][Full Text] [Related]
9. The assessment in man of the beta-adrenoceptor blocking activity and cardioselectivity of H-I 42 BS, a long acting beta-adrenoceptor blocking drug.
Pringle TH; Deering AH; Scott MG; Harron DW; Shanks RG
Br J Clin Pharmacol; 1987 Apr; 23(4):411-23. PubMed ID: 2883988
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of single oral doses of the new beta-adrenoceptor blocking agents betaxolol (SL 75212) in healthy volunteers.
Cadigan PJ; London DR; Pentecost BL; Bianchetti G; Gomeni R; Kilborn JR; Morselli PL
Br J Clin Pharmacol; 1980 Jun; 9(6):569-75. PubMed ID: 6104498
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of epanolol. Pharmacodynamic aspects.
Harry JD
Drugs; 1989; 38 Suppl 2():18-27. PubMed ID: 2575976
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
Czendlik CH; Sioufi A; Preiswerk G; Howald H
Eur J Clin Pharmacol; 1997; 52(6):451-9. PubMed ID: 9342580
[TBL] [Abstract][Full Text] [Related]
13. Oral pharmacokinetics of bisoprolol in resting and exercising healthy volunteers.
Le Coz F; Sauleman P; Poirier JM; Cuche JL; Midavaine M; Rames A; Lecocq B; Jaillon P
J Cardiovasc Pharmacol; 1991 Jul; 18(1):28-34. PubMed ID: 1719288
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of epanolol after acute and chronic oral dosing in elderly patients with stable angina pectoris.
Hosie J; Scott AK; Petrie JC; Cockshott ID
Br J Clin Pharmacol; 1990 Mar; 29(3):333-7. PubMed ID: 1968755
[TBL] [Abstract][Full Text] [Related]
15. Effects of epanolol and metoprolol on the heart measured by 24-hour holter monitoring.
Withagen AJ; Corbeij HM; Huige MC; Kragten JA; Vermeulen A
Drugs; 1989; 38 Suppl 2():67-9. PubMed ID: 2575985
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of epanolol (ICI 141,292) in healthy young volunteers and comparative data in elderly patients with angina and subjects with renal or hepatic impairment.
Cockshott ID
Drugs; 1989; 38 Suppl 2():10-7. PubMed ID: 2575975
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
[TBL] [Abstract][Full Text] [Related]
18. Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man.
Arnold JM; O'Connor PC; Riddell JG; Harron DW; Shanks RG; McDevitt DG
Br J Clin Pharmacol; 1985 May; 19(5):619-30. PubMed ID: 2860915
[TBL] [Abstract][Full Text] [Related]
19. Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist.
O'Connor PC; Arnold JM; Brown AN; Francis RJ; Finch MB; Galloway DB; Harron DW; McDevitt DG; Shanks RG
Br J Clin Pharmacol; 1985 Mar; 19(3):319-27. PubMed ID: 2859047
[TBL] [Abstract][Full Text] [Related]
20. The selectivity of xamoterol, prenalterol, and salbutamol as assessed by their effects in the presence and absence of ICI 118,551.
McCaffrey PM; Riddell JG; Shanks RG
J Cardiovasc Pharmacol; 1988 May; 11(5):543-51. PubMed ID: 2455840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
